TAK
Takeda Pharmaceutical Company Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum-Eingaben (vergleichbare Manager):
Halterbreite +16.7% ·
Aktienfluss -1.0% ·
neue Nettopositionen +14.3%
— Formel
Eigentümerfragmentierung — mehr Halter, kleinere Gesamtbeteiligung
Alle Eigentumszahlen: nur beobachtete 13F-Manager, Stammaktienpositionen, Berichtszeitraum Q3 2025
| Quartal | Inhaber | Δ | Aktien | Gemeldeter Wert | Neu | Ausstiege |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | +7 | 88.72M | $1.46B | +9 | −2 |
| Q1 2026 | 81 | +2 | 81.32M | $1.54B | +7 | −5 |
| Q4 2025 | 79 | -2 | 68.50M | $1.10B | — | −2 |
| Q3 2025 | 14 | +2 | 31.18M | $456.42M | +3 | −1 |
| Q2 2025 | 9 | -3 | 18.36M | $283.88M | — | −3 |
| Q1 2025 | 9 | +1 | 8.73M | $129.81M | +2 | −1 |
| Q4 2024 | 8 | +3 | 9.62M | $127.30M | +4 | −1 |
| Q3 2024 | 5 | 0 | 11.53M | $98.50M | +1 | −1 |
| Q2 2024 | 5 | — | 10.02M | $129.64M | — | — |
| # | Manager | Aktien | Δ Anteile | Wert | Deren Gewichtung | Gehalten | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Goldman Sachs Group ✦ | 4.95M | — | $72.52M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Goldman Sachs Group ✦ | 4.95M | — | $72.52M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Goldman Sachs Group ✦ | 4.95M | — | $72.52M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 4.19M | +2.1% | $61.30M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Fidelity (FMR) ✦ | 4.19M | +2.1% | $61.30M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 4.19M | +2.1% | $61.30M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | Fidelity (FMR) ✦ | 4.19M | +2.1% | $61.30M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Renaissance Technologies ✦ | 3.86M | +17.1% | $56.58M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 18 | BlackRock ✦ (passiv) | 3.31M | -6.8% | $48.42M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | BlackRock ✦ (passiv) | 3.31M | -6.8% | $48.42M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Arrowstreet Capital ✦ | 2.83M | +132.1% | $41.41M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Millennium Management ✦ | 2.56M | -17.2% | $37.42M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 766.28K | +107.6% | $11.22M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 766.28K | +107.6% | $11.22M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 766.28K | +107.6% | $11.22M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 766.28K | +107.6% | $11.22M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 26 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 33 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 34 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 35 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 36 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 37 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 38 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 39 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 40 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 41 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 42 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 43 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 44 | D. E. Shaw & Co. ✦ | 281.29K | Neu | $4.12M | 0.0% | New | 1 | SEC ↗ |
| 45 | The Vanguard Group ✦ (passiv) | 101.87K | 0.0% | $1.49M | 0.0% | Held | 2 | SEC ↗ |
| 46 | Citadel Advisors ✦ | 75.62K | Neu | $1.11M | 0.0% | New | 1 | SEC ↗ |
| 47 | Fisher Asset Management ✦ | 40.48K | -59.0% | $592,686 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 48 | Marshall Wace ✦ | 27.77K | Neu | $406,494 | 0.0% | New | 1 | SEC ↗ |
| 49 | Marshall Wace ✦ | 27.77K | Neu | $406,494 | 0.0% | New | 1 | SEC ↗ |
„Ihre Gewichtung" = Anteil der Position am gemeldeten 13F-Eigenkapitalwert des jeweiligen Managers — das Conviction-Maß. ✦ = kuratorisch ausgewählter Manager.
Neue Käufer
| D. E. Shaw & Co. | $4.12M | 0.0% |
| Citadel Advisors | $1.11M | 0.0% |
| Marshall Wace | $406,494 | 0.0% |
| Marshall Wace | $406,494 | 0.0% |
Ausgestiegen
| Adage Capital Partners | $39.17M | war 0.1% |
Marktweiter Kontext: über ALLE 13F-Melder (strukturierte SEC-Daten, Q1 2026): 356 Inhaber, 97.72M Anteile, $1.74B gemeldet. Dies ist ein anderer, älterer Zeitraum als die oben genannten Zahlen des erfassten Universums; beide werden niemals vermischt.
Was die erfassten Halter dieses Wertpapiers am häufigsten sonst noch halten — Zählungen gemeinsamer Eigentümerschaft, keine fundamentalen Zusammenhänge.
Käufe auf dem offenen Markt (P)
Keine Insider-Käufe auf dem offenen Markt in unserem Erfassungszeitraum.
Verkäufe auf dem offenen Markt (S)
Officer, Director · 19.65K Ant. · $363,347
Officer · 12.98K Ant. · $235,118
Officer · 50.01K Ant. · $855,205
Officer · 47.59K Ant. · $813,721
Officer · 14.01K Ant. · $239,503
Officer · 30.87K Ant. · $527,843
Officer · 975 Ant. · $17,062
Officer · 33.63K Ant. · $588,715
Officer · 6.77K Ant. · $115,835
Officer · 7.28K Ant. · $124,437
Zuteilungen, Ausübungen und Steuereinbehalte werden hier nie als Käufe oder Verkäufe gezählt. Methodik